Posted by Michael Wonder on 19 Sep 2023
UCB provides update on US regulatory review of bimekizumab
19 September 2023 - UCB today provided an update on the biologics license application for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis.
UCB has received the establishment inspection report from the US FDA following the pre-license inspection conducted in April 2023 at the Belgium manufacturing facility. The FDA has concluded that this inspection is successfully closed.
